Rarebase
Katherine Dyer is a seasoned research professional currently serving as a Senior Research Associate in Translational Research at Transcripta Bio since October 2023. Previously, Katherine held the position of Research Associate II in Phenotypic Screening at Transcripta Bio and in Toxicology at Vertex Pharmaceuticals, where Katherine implemented in-vitro genetic toxicology assays and conducted validation efforts with Litron Laboratories. Additional experience includes roles as a Quality Assurance Specialist at ImmunoTek Bio Centers, an Analytical Technician and Biomedical Technician at RTI Surgical®, and an Undergraduate Research Assistant at the Medical University of South Carolina, where work focused on neuroscience and addiction research. Katherine holds a Master of Science in Biology from Georgia State University and a Bachelor’s degree in Biology from the College of Charleston.
Rarebase
Rarebase is enabling a better life for the 400 million people living with rare disease. With a product engine designed to discover treatments for hundreds of monogenic diseases simultaneously, Rarebase is focused on the largest untapped drug discovery opportunity in human health: rare diseases. Rarebase has already uncovered potential treatments for hundreds of rare diseases. The company has also built a “drug-gene atlas” to enable AI-driven drug discovery.